GLPwatch

Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method.

ACS Comb Sci · 2020

Last updated 2026-05-28

Researchers developed a new, simpler method to produce semaglutide, a drug used to treat type 2 diabetes. Using a special technique called soluble hydrophobic-support-assisted liquid-phase synthesis, they improved the total yield to 30% and increased the purity of the final product. The process involved optimizing reaction conditions and refining post-synthesis treatments.

AI summary of the abstract below.

JournalACS Comb Sci, 2020
Citations14
Relative citation ratio0.81
NIH percentile43
Molecules semaglutide
Conditions studied Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease

Abstract

Considering the high cost of the production of semaglutide, which is currently the most promising antidiabetic drug especially for the treatment of type 2 diabetes mellitus, a new synthetic route of semaglutide production that possesses excellent yield and high purity is of vital importance. Herein, we reported a newly developed synthetic route of semaglutide that is simple and efficient, based on a soluble hydrophobic-support-assisted liquid-phase synthetic method by applying Alloc-chemistry to the synthesis of the main chain peptide and side chain peptide of semaglutide. With careful optimization of the reaction conditions and innovative strategy of post-synthetic treatments, the total yield and purity of the crude semaglutide was improved satisfactorily.

Verbatim abstract via PubMed 33058727 ↗

Related research